What is the importance of genotype changes in the diagnosis of malignant hyperthermia?;Welche Bedeutung haben Genotypveranderungen in der Diagnostik der malignen Hyperthermie?

Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie

Volumn 31, Issue 6, 1996, Pages 334-343

  Steinfath, M ^a   Scholz, J ^a   Singh, S ^a   Wappler, F ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

diagnostics; genotype changes; malignant hyperthermia; preoperative screening

Indexed keywords

BIOLOGICAL MARKER; CALCIUM CHANNEL; MUSCLE PROTEIN; RYANODINE RECEPTOR;

CHROMOSOME 3; CHROMOSOME 7; GENOTYPE; HUMAN; MALIGNANT HYPERTHERMIA; PHENOTYPE; REVIEW; SCREENING; CHROMOSOME 17; CHROMOSOME 19; CHROMOSOME ABERRATION; CHROMOSOME MAP; GENETIC MARKER; GENETICS; RISK FACTOR;

CALCIUM CHANNELS; CHROMOSOME ABERRATIONS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 19; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 7; GENETIC MARKERS; GENOTYPE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE PROTEINS; PHENOTYPE; RISK FACTORS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 0029839645     PISSN: 09392661     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995932     Document Type: Review

References (96)

1. Ball SP, Johnson K J: The genetics of malignant hyperthermia. J. med. Genet. 1993;30:89-93
2. 2 monitoring. Its use in the diagnosis and management of malignant hyperthermia. Anaesthesia 1984;39:1000-1003
3. Berman MC, Harrison GG, Dutoit P, Bull JE, Keuch J E: Halothane-induced hyperpyrexia in landrace pigs. S. Afr. Med. J. 1969; 43:545
4. Berridge MJ: Inositol trisphosphate and calcium signalling. Nature 1993;361:315-325
5. Britt BA: Malignant hyperthermia: A review: In: Milton AS (Hrsg): Pyretics and antipyretics. Springer, Berlin, Heidelberg, New York (Handbook of experimental pharmacology, Vol. LX) 1982:547-615
6. Britt BA: Heriditary and epidemiological aspects of malignant hyperthermia. In: Nalda Felipe MA, Gottmann S, Khambatt HJ (Hrsg): Malignant hyperthermia. Current concepts. Normed, Englewood 1989:19-39
7. Brownell A: Malignant hyperthermia: relationship to other disease. Brit. J. Anaesth. 1988;60:303-308
8. Carroll JB: Increased incidence of masseter spasm in children with strabismus anesthetized with halothane and succinylcholine. Anesthesiology 1987;67:559-561
9. Chalkadis GA, Branchi KG: Cardiac arrest after isoflurane anaesthesia in a patient with Duchenne's muscular dystrophy. Anaesthesia 190;45:22-25
10. Davis W, Harbitz I, Fries R, Stranzinger G, Hauge JG: Porcine malignant hyperthermia carrier detection and chromosomal assignment using linked probe. Anim. Genet. 1988;19:203-212
11. Denborough MA: Malignant hyperpyrexia. Med. J. Aust. 1977;2:757-758
12. Denborough MA, Dennett X, Anderson R: Central core disease and malignant hyperpyrexia. Brit. Med. J. 1973;1:272-273
13. Denborough M A, Lovell R R H: Anaesthetic deaths in a family. lancet 1960;2:45
14. Deufel T, Colla A, Iles D, Meindl A, Meitinger T, Schindelhauer D, DeVries A, Pongartz D, MacLennan DM, Johnson KJ, Lehmann-Horn F: Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Amer. J. Hum. Genet. 1992;50:1151-1161
15. Deufel T, Sudbrak R, Feist Y, Rübsam B, Du Chesne I, Schafer KL, Roewer N, Grimm T, Lehmann-Horn F, Hartung E J, Muller CR: Discordance, in a malignant hyperthermia pedigree, between in vitor contracture-test phenotype and haplotypes for the MHSI region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Amer. J. Hum. Genet. 1995;56:1334-1342
16. Eberlein HJ: Therapie der malignen Hyperthermie. Vorläufige Mitteilung. Anaesthesist 1979;28:247-248
17. European Malignant Hyperthermia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Brit. J. Anaesth. 1984;56:1267-1269
18. Fagerlund T, Islander G, Ranklev E, Harbitz I, Hauge JG, Mokleby E, Berg K: Genetic recombination between malignant hyperthermia and calcium release channel in skeletal muscle. Cin. Genet. 1992;41:270-272
19. Fill M, Coronado R, Mickelson JR, Vilven J, Ma JJ, Jacobson BA, Louis CF: Abnormal ryanodine receptor channels in malignant hyperthermia. Biophys. J. 1990;57:471-475
20. ++ relase channels in malignant hyperthermic skeletal muscle. Biophys. J. 1991;59:1085-1090
21. Fletcher JE, Tripolitis L, Hubert M, Vita GM, Levitt RC, Rosenberg H: Genotype and phenotype relationship for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia. Brit. J. Anaesth. 1995;75:307-310
22. Foster PS, Gesini E, Glaudianos C, Hopkinson KC, Denborough MA: Inositol 1,4,5-triphosphate phosphatase deficiency and malignant hyperthermia in swine. Lancet 1989;2:124-127
23. Frank JP, Harati Y, Butler J, Nelson TE, Scott CI: Central core disease and malignant hyperthermia syndrome. Ann. Neurol. 1980;17:11-17
24. Fujii J, Otsu K, Zorzato F, De Leon S, Hanna VK, Weiler JE, O'Brien J, MacLennan DH: Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991;253:448-451
25. Gerdes C, Richter A, Annies R, Loscher W: Increase of serotonin in plasma during onset of halothane-induced malignant hyperthermia in pigs. Eur. J. Pharmacol. 1992;220:91-94
26. Gibson C, Tuttle JJ: Heat stroke as a post-operative complication. Med. News (NY) 1900;77:883-884
27. Gillard EF, Otsu K, Fujii J, Khanna VK, De Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan D H: A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991; 11:751-755
28. Gillard EF, Otsu K, Fujii J, Duff C, De Leon S, Khanna VK, Britt BA, Mac Lennan DH: Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RyR1) gene in individuals with malignant hyperthermia. Genomics 1992;13:1247-1254
29. Hall LW, Woolf N, Bradley JWP, Jolly DW: Unusual reaction to suxamethonium chloride. Brit. Med. J. 1966;2:1305
30. Harbitz I, Chowdhary B, Thomsen PD, Davies W, Kaufmann U, Ran S, Gustavsson I, Christensen K, Hauge JG: Assignment of the porcine calcium release channel gene, a candidate for the malignant hyperthermia locus, to the 6p11-qq21 segment of chromosome 6. Genomics 1990;8:243-248
31. Harriman DGF: Preanesthetic investigation of malignant hyperthermia: Microscopy. Int. Anesthesiol. Clin 1979;17:97-117
32. Harrison GG: Control of malignant hyperpyrexia syndrome in MHS swine by dantrolene sodium. Brit. J. Anaesth. 1975;47:62-65
33. Heiman-Patterson TD, Natter HM, Rosenberg HR, Fletcher JE, Tahmoush AJ: Malignant hyperthermia susceptibility in X-linked muscle dystrophies. Pediatr. Neurol. 1986;2:356-358
34. Heiman-Patterson TD, Rosenberg HR, Binning CPS, Tahmoush AJ: King-Denborough syndrome: Contracture testing and literature review. Pediatr. Neurol. 1986;2:175-177
35. Heiman-Patterson TD, Martino C, Rosenberg HR, Fletcher JE, Tahmoush AJ: Malignant hyperthermia in myotonia congenita. Neurology 1988;38:810-812
36. Hopkins PM, Ellis FR, Halsall PJ: Ryanodine contracture: a potentially specific in vitro diagnostic test for malignangt hyperthermia. Br J Anaesth 1991;66:611-613
37. Houde A, Pommier SA, Roy R: Detection of the ryanodine receptor mutation associated with malignant hyperthermia in purebred swine populations. J. Anim. Sci. 1993;71:1414-1418
38. Iles DE, Segers B, Heytens L, Sengers RCA, Wieringa B: High-resolution physical mapping of four microsatellite repeat markers near the RYR1 locus on chromosome 19q13.1 and apparent exclusion of the MHS locus from this region in two malignant hyperthermia susceptible families. Genomics 1992;14:749-754
39. Iles DE, Segers B, Sengers RCA, Monsieurs K, Heytens L, Halsall PJ, Hopkins PM, Ellis F R, Hall-Curran JL, Stewart AD, Wieringa B: Genetic mapping of the β1- and gamma-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibility. Hum. Mol. Genet. 1993; 2:863-868
40. Iles DE, Lehmann-Horn F, Scherer SW, Tsui L-C, Olde Weghuis D, Suijkerbuijk RF, Heytens L: Localisation of the gene encoding the alpha2/delta-subunits of the L-type voltage dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia suceptible families. Hum. Mol. Genet. 1994;3:959-975
41. Isaacs H, Badenhorst M: False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993;79:5-9
42. Johnson K.: Malignant hyperthermia hots up! Hum. Mol. Genet. 1993;2:849
43. Karlow W, Britt BA, Terrau ME, Haist C: Metaboic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970;2:895-898
44. Keating KE, Quane KA, Manning BM, Lehane M, Hartung E, Censier K, Urwyler A, Klausnitzer M, Muller CR, Heffron JJA, McCarthy TV: Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Hum Mol. Genet. 1994;3: 1855-1858
45. Kim DH, Sreter FA, Ohnishi ST, Ryan JF, Roberts J, Allen PD, Meszaros LG, Antoniu B, Ikemoto N: Kinetic studies of calcium release from sarcoplasmic reticulum of normal and MHS pig muscle. Biochim. Biophys. Acta 1984;175:320-327
46. Krivosic-Horber R, Adnet P, Reyford, Krivosic I: Problems in malignant hyperthermia epidemiology. Proceedings of the Annual Meeting of the Eurpean Malignant Hyperthermia Group, 1995;8-15
47. Lai FA, Erickson HP, Russeau E, Liu QY, Meissner G: Purificarin and reconstitution of the calcium release channel from skeletal muscle. Nature 1988;331:315-319
48. Levin RC, Nouri N, Jedlicka AE, McKusick VA, Marks AR, Shutack JG, Fletcher JE, Rosenberg H, Meyers DA: Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics 1991;11:543-547
49. Levitt RC, Olckers A, Meyers S, Fletcher JE, Rosenberg H, Isaacs H, Meyers DA: Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 1992;14:562-566
50. Levitt RC: Prospects for the Diagnosis of malignant hyperthermia susceptibility using molekular genetic approaches. Anesthesiology 1992;76:1039-1048
51. Löscher W, Witte U, Fredow G, Ganter M, Bickhardt K: Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: Stimulation of 5-HT2 receptors induces malignant hyperthermia. Naunyn-Schmiedeberg's Arch. Pharmacol. 1990;34:483-493
52. MacKenzie AE, Korneluk G, Zorzato F, Fujii J, Phillips MS, Iles D, Wieringa B, Eblond S, Bailly J, Willard HF, Duff C, Worton RG, MacLennan DH: The human ryanodine receptor gene: Its mapping to 19q13.1, placement in a chromosome 19 linkage group, and exclusion as the gene causing myotonic dystrophy. Amer. J. Hum. Genet. 1990;46:1982-1989
53. MacLennan DH, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk RG, Frodis W, Britt BA, Worton RG: Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990;343:559-561
54. MacLennan DH, Phillips MS: Malignant hyperthermia. Science 1992;256:789-794
55. Mariani P, Johansson M, Ellegren H, Harbitz I, Juneja RK, Andersson L: Multiple restriction fragment length polymorphisms in the porcine calcium release channel gene (CRC): assignment to the halothane (HAL) linkage group. Anim. Genet. 1992;23: 257-262
56. Mauritz W, Sporn P, Steinbreitner K: Maligne Hyperthermie in Osterreich, I. Epidemiology und Klinik. Anaesthesist 1986;5: 639-650
57. Mauritz W, Hackl W, Sporn P, Graf M, Sluga E, Sreinbreitner K: Maligne Hyperthermie in Osterreich. II. Vergleich der Ergebnisse diagnostischer Testverfahren. Anaesthesist 1988;37:425-431
58. McCarthy TV, Healy JMS, Heffron JJA, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K: Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990;343:562-564
59. McCarthy TV: Developments in the genetics of MH. Proceedings of the Annual Meeting of the European Malignant Hyperthermia Group, 1995;88-98
60. Meier-Hellmann A, Romer M, Hannemann L, Kersting T, Reinhart K: Früherkennung einer malignen Hyperthermie durch Capnometrie. Anaesthesist 1990;39:41-43
61. ++ induced calcium release by isolated sarcoplasmic reticulum vesicles from malignant hyperthermia susceptible pig muscle. Biochim. Biophys. Acta 1986;862:318-328
62. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF: Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J. Biol. Chem. 1988;263:9310-9315
63. Moschcowitz A von: Postoperative heatstroke. Surg. Gynecol. Obstet. 1916;23:443-451
64. Nelson TE: Abnormality in calcium release from skeletal sarcoplasmic reticulum of pigs suceptible to malignant hyperthermia. J. Clin. Invest. 1983;72:862-872
65. Obredanne L: De l'influence de'l anesthesique-employe dans la genese chez les nourrissons. Rev. Med. Fr. 1929;10:617
66. Ooms L, Awoutera F, Degryse A, Jageneau T: Serotonin and S2 antagonists in veterinary. In: Ruckebusch Y, Toutain PL, Koritz GD (Hrsg): Veterinary pharmacology and toxicology. MTP Press, Boston. The Hague, Dordrecht 1983;263-281
67. Ørding H: Incidence of malignant hyperthermia in Denmark. Anesth. Analg. 1985;64:700-704
68. Otsu K, Khanna VK, Archibald AL, MacLennan DH: Cosegregation of porcine malignant hyperthermia and a probable causal mutation in the skeletal muscle ryanodine receptor gene in backcross families. Genomics 1991;11:744-750
69. Püschel K, Koops E, Schulz-Baldes JG: Postoperative maligne Hyperthermie bei einem 7 Tage alten Säugling? Anaesthesist 1989;38:81-84
70. Quane KA, Healy JMS, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ording H, Bendixen D, Mortier W, Linz U, Muller CR, McCarthy TV: Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genet. 1993;5:51-55
71. Quane KA, Keating KE, Healy JMS, Manning BM, Krivosic-Horber R, Krivosic I, Monnier N, Lunardi J, McCarthy TV: Mutation screening of the RYR1 gene in malignant hyperthermia: Detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 1994;23:236-239
72. Quane KA, Keating KE, Manning BM, Healy JMS, Monsieurs K, Heffron JJA, Lehane M, Heytens L, Krivosic-Horber R, Adnet P, Ellis FR, Monnier N, Lunardi J, McCarthy TV: Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum. Mol. Genet 1994;3:471-476
73. Rempel WE, Lu MY, Kandelgy AE, Kennedy CFH, Irvin LR, Mickelson JR, Louis CF: Relative accuracy of the halothane challenge test and a molecular genetic test in detecting the gene for porcine stress syndrome. J. Anim. Sci. 1993;71:1395-1399
74. Roewer N: Maligne Hyperthermie heute. Anaesth. Intensivmed. Notfallmed. Schmerzther. 1991;26:431-449
75. Roewer N: Herz und Kreislauf bei maligner Hyperthermie. Anaesthesiologie und Intensivmedizin 221, Springer 1992; 1-247
76. Saidman L, Havard E, Egger E: Hyperthermia during anaesthesia, J. Amer. Med. Ass. 1964;190:1029-1032
77. Scholz J, Roewer N, Rum U, Schmitz W, Scholz H, Schulte am Esch J: Possible involvement of inositol-lipid metabolism in malignant hyperthermia. Brit. J. Anaesth. 1991;66:692-696
78. Scholz J, Troll U, Schulte am Esch J, Hartung E, Patten M, Sandig P, Schmitz W: Inositol-1,4,5-trisphosphate and malignant hyperthermia. Lancet 1991;337:1361
79. Scholz J, Steinfath M, Roewer N, Patten M, Troll U, Schmitz E, Scholz H, Schulte am Esch J: Biochemical changes in malignant hyperthermia susceptible swine: cyclic AMP, inositol phosphates, alpha1-, beta1- and beta2-adrenoceptors in skeletal and cardiac muscle. Acts Anaesthesiol. Scand. 1993;37:575-583
80. Scholz J, Wappler F, Steinfath M, Köchling A, Roewer N, Schulte am Esch J: Measurement of inositol 1,4,5-trisphosphate in blood from individuals susceptible to malignant hyperthermia. Anaesthesiology 1995;83:A348
81. Sethna NF, Rockoff MA, Worthen HM, Rosnow JM: Anesthesia-related complication in children with Duchenne muscular dystrophy. Anesthesiology 1988;68:462-465
82. Snyder HR, Davis CS, Dickerton RK, Halliday C: 1-((5-Arylfufurylidine)amino)hydantoins. A new class of muscle relaxants. J. med. Chem. 1967;10:807-810
83. Sold M, Tschöp M, Sörensen N: Symptome der akuten Einklemmung nach Narkoseemleitung bei Hydrocephalus - in Wahrheit eine maligne Hyperthermie. Anaesthesist 1986;35: 634-638
84. Steinfath M, Singh S, Scholz J, Becker K, Lenzen C, Wappler F, Köchling A, Roewer N, Schulte am Esch J: C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response. J. Mol. Med. 1995;73:35-40
85. Stewart CR, Kahler SG, Cilchrist JM: Congenital myopathy with cleft palate and increased susceptibility to malignant hyperthermia: King Syndrome? Pediatr. Neurol. 1988;4:371-374
86. Sporn P, Mauritz W, Steinbreitner K: Diagnostik der malignen Hyperthermie. In: Jantzen J P, Gottmann S (Hrsg): Maligne Hyperthermie. Thieme, Stuttgart - New York 1986;40-51
87. Sudbrak R, Golla A, Hogan K, Powers P, Gregg R, Du Chesne I, Lehmann-Horn F, Deufel T: Exclusion of malignant hyperthermia susceptibility (MHS) from a putative MHS2 locus on chromosome 17q and of the alpha1, β1, and gamma subunits of the dihydropyridine receptor calcium channel as candidates for the molecular defect. Hum. Mol. Genet. 1993;2:857-862
88. Sudbrak R, Procaccio V, Klausnitzer M, Curran JL, Monsieurs K, Van Broeckhoven C, Ellis R, Heyetens L, Hartung EJ, Kozak-Ribbens G, Heilinger D, Weissenbach J, Lehmann-Horn F, Mueller CR, Deufel T, Stewart AD, Lunardi J: Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Amer. J. Hum. Genet. 1995;56:684-691
89. Wappler F, Roewer N, Lenzen C, Scholz J, Steinfath M, Rumberger E, Schulte am Esch J: Hochreines Ryanodin zur in-vitro-Diagnostik der Malignen Hyperthermie. Anaesth. Intensivmed. Notfallmed. Schmerzther. 1993;28:427-431
90. Wappler F, Roewer N, Lenzen C, Köchling A, Scholz J, Steinfath M, Schulte am Esch J: High-purity ryanodine and 9.21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man. Brit. J. Anaesth. 1994;72:240-242
91. Wappler F, Roewer N, Kochling A, Scholz J, Steinfath M, Rumberger E, Loscher W, Schulte am Esch J: Effekte von Serotonin-2-Rezeptoragonisten auf Skelettmuskelpräparate von Patienten mit Disposition zu maligner Hyperthermie. Anaesthesist 1993; 44:238-244
92. Wappler F, Roewer N, Köchling A, Scholz J, Löscher W, Steinfath M, Schulte am Esch J: Effects of the serotonin-2 receptor agonist DOI on skeletal muscle specimen of malignant hyperthermia susceptible patients. Anesthesiology 1996;84:1280-1287
93. Wappler F, Roewer N, Kochling A, Scholz J, Steinfath M, Schulte am Esch J: In vitro-diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth. Analg 1996;82:1230-1236
94. Wedel DJ, Nelson TE: Malignant hyperthermia - diagnostic dilemma: false-negative contracture responses with halothane and caffeine alone. Anesth. Analg. 1994;78:787-792
95. Zhang Y, Chen HS, Khanna VK, De Leon S, Philips MS, Schappert K, Britt BA, MacLennan DH: A mutation in the human ryanodine receptor gene associated with central core disease. Nature Genet 1993;5:46-50
96. Zorzato F, Fujii J, Otsu K, Phillips MS, Green NM, Lai FA: Meissner G, MacLennan DH: Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J. Biol. Chem. 1990;265:2244-2256